Biotech_Jack (@biotech_jack) header
Biotech_Jack (@biotech_jack) profile picture
Mars
Joined June 2021
Photo by Biotech_Jack (@biotech_jack)Photo by Biotech_Jack (@biotech_jack)Photo by Biotech_Jack (@biotech_jack)Photo by Biotech_Jack (@biotech_jack)Photo by Biotech_Jack (@biotech_jack)Photo by Biotech_Jack (@biotech_jack)Photo by Biotech_Jack (@biotech_jack)Photo by Biotech_Jack (@biotech_jack)Photo by Biotech_Jack (@biotech_jack)Photo by Biotech_Jack (@biotech_jack)
This are only the shorts on french shares.
Abivax : Shay Capital franchit le seuil de publication, 0,59 % du capital vendu à découvert. Déclaré à l'AMF le 17 novembre. 5 fonds sont déclarés vendeurs, 5,67 % du capital au total. $ABVX
149
$ABVX new patent granted "Quinoline derivatives for use in treatment of inflammation diseases"
1
9
1,121
I really don’t like how is left hand is moving
Stanley Druckenmiller: "We're looking for AI use cases as opposed to infrastructure" "Maybe the most interesting use case is a lab..." "I don't personally believe they're gonna be in the token business for much longer...you can start selling tasks"
7
9
4
465
134,430
Biotech_Jack retweeted
AMD CEO Lisa Su says Nvidia is a phenomenal company and Jensen has been a tremendous leader, but AMD has to separate itself from the noise "First of all, Nvidia is a phenomenal company. Jensen has been a tremendous leader for the industry, a great leader." "There is a lot going on. What I try to do from an AMD standpoint, and from an industry standpoint, is, look, we have to separate a little bit from the noise. The noise will work itself out in time." "But taking a step back, from an AMD standpoint, we are in a place where we have just tremendous opportunity." "Tremendous opportunity to be part of this infrastructure buildout, to work collectively with our partners on the roadmap going forward, to, I'm not gonna say overpromise, but to promise and exceed expectations in terms of delivery."
AMD CEO Lisa Su says this semiconductor cycle does not look cyclical, it looks ‘generational’ "I think this one is a little different." "Typically, the semiconductor market has been known to be a cyclical market. When demand is high, you build a lot, and then you satisfy that demand, and then there's a little bit of a digestion period." "We are not seeing that today. We're not seeing something that looks cyclical. We're seeing something that looks generational in terms of the growth that's required." "Because AI is eventually making every company, every enterprise, more productive, and so you're willing to invest in that productivity so that you build better products. It's like a virtuous, positive cycle." "Now, that being the case, we are always looking at ensuring that the investment is coincident with the return on investment. That's a very regular conversation that we have. But this cycle does feel quite different."
2
24
5
179
240,811
$ABVX Top5 ADR Holder 1/ Helikon Investments Ltd 4,222,896 4.82% Darwin Global Management Ltd 4,021,583 4.59% Vestal Point Capital LP 3,960,000 4.52% TCG Crossover Management LLC 3,663,038 4.18% Adar1 Capital Management LLC 2,050,822 2.34%
2
29
2,914
$ABVX ADR 2/2 HIGEST INCREASE OR NEW POSITION Jupiter Topco LLC +1,913,933 (New) 2.19% Vestal Point Capital LP +1,610,557 (Incr) 4.52% Helikon Investments Ltd +1,435,765 (Incr) 4.82% RA Capital Management LP +1,132,557 (New) 1.29% Norges Bank +1,100,000 (New) 1.26%
1
5
853
GS: We forecast the S&P 500 will rise by 17% to 8,700 by year-end 2027
16
45
11
361
48,892
$PHVS Top 5 holders 1/ FMR LLC (Fidelity) 6,921,820 9.86% Wellington Management Group LLP 6,696,804 9.54% Foresite Capital Management LLC 5,442,723 7.75% venBio Partners LLC 4,458,977 6.35% EQT AB (including LSP V) 3,424,609 4.88%
1
207
$PHVS 2/ Wellington Management Group LLP (13G) +4,303,870 6.13% (Total: 9.54%) Point72 Asset Management LP (ULT-AGG) +1,258,567 1.79% (Total: 4.13%) Vanguard Group Inc. (ULT-AGG) +1,174,010 1.67% (Total: 1.91%) Tetragon Partners GP Ltd (13F) +542,620 0.77% (Total: 1.19%)
1
146
$PHVS 3/3 Polar Capital Partners Ltd (ULT-AGG) +466,979 0.67% (Total: 3.98%)
125
$NAMS Top 5 Holder Frazier Life Sciences Management LP 18,988,902 15.83% Capital Group Cos Inc/The 14,723,654 12.28% FMR LLC (Fidelity) 11,941,763 9.96% RA Capital Management LP 9,550,191 7.96% Forbion 8,490,353 7.08% 1/
1
4
406
$NAMS 2/2 Jupiter Topco LLC +2,535,682 (New) 2,535,682 2.11% Bain Capital Life Sciences +1,632,646 (Incr) 3,806,559 3.17% Two Sigma Investments LP +1,123,080 (incr) 1,135,081 0.95% Capital Group Cos Inc/The +769,602 (incr) 14,723,654 12.28% Norges Bank +645,383 (incr) 1,134,823
1
120
Patience
4
17
1
182
8,783
Druckenmiller increase $NAMS holdings
Druckenmiller 13F summary: - bought STX (and calls), NEM, APP, SPCX, PLTR, - added AMZN, U, FOXA, - reduced TSMC, STM, INSM, PANW - dumped SNDK, EWZ, GOOGL, UAL
4
308
Biotech_Jack retweeted
🚨 BREAKING GOOGLE JUST CAUGHT THE FIRST CYBERATTACK RUN BY AI END TO END, WITH NO HUMAN IN THE LOOP! A RUSSIAN-SPEAKING CREW'S "EXPLOIT_AGENT" READ NEW SOFTWARE PATCHES, WROTE THE EXPLOITS AND RAN THEM ON ITS OWN, AS 22 ZERO-DAYS WERE EXPLOITED IN AUGUST ALONE. THIS IS NOT LOOKING GOOD FOR EVERY COMPANY ONLINE...
264
1,852
270
8,651
849,863
Our work in cardiovascular disease is only the beginning. At #CTAD2026, we will share insights that reflect our commitment to advancing a deeper understanding of neurodegenerative conditions, including research from the Phase III BROADWAY trial and information on the Phase 2b SPINOZA study in early Alzheimer’s disease. We look forward to joining fellow industry experts in Boston to discuss the latest advances and developments in Alzheimer’s disease clinical research.
184
Biotech_Jack retweeted
My outlook on $ABVX - What is there to say that hasn't been said? Whatever, here I go anyway... In the $83s right now I think it has to be one of the worst mispricings (and thus, hopefully, best opportunities) I have ever seen in biotech. Honestly, given the post P3 status of this asset...I would probably be pretty comfortable calling it "the" worst mispricing I've seen. The stock's performance this year has *easily* been the most frustrating disappointment I've experienced in >10 years of doing this. The stock is down almost 40% YTD, and its underperformance versus the $XBI this year is nearly -70%. What makes this price action so particularly infuriating is how incredibly positive their updates throughout the year have been. I would've guessed that $ABVX languishing in the $80s would have been the result of a mixed UC maintenance readout, perhaps with a CR delta around 20% or below...The reality was *twice* that (~40%) - tying the best clinical remission data *ever* shown (by multi-black box warning drug Rinvoq). And on top of that we got an even bigger blue sky surprise with truly unheard of, unprecedented endoscopic remission rates... ...Then, on top of that, a few months later an unrelated trial reads out at UEGW that once and for all confirms that the endpoint GI docs should be treating to is...Endoscopic remission! The exact endpoint where the runner up to $ABVX isn't even visible in the rear view mirror...On their recent call, $ABVX management called this a "perfect storm". I agree. Not only did they present ER data so positive that nobody had even *modelled* for it as a *possibility*, but then just a few months later, that very endpoint becomes *THE* key endpoint for the disease...incredible!
17
15
5
281
40,899
Miners Negotiate Cross-Border Tie-Ups to Unlock Argentina Copper Mining companies are discussing potential cross-border partnerships as Argentina’s emerging copper industry looks to tap infrastructure and expertise on the Chilean side of the Andes, according to Chile’s top mining official. “It’s natural,” Mas said of the cooperation between companies. “The government wants to be a facilitator. We want the private sector to develop its ideas.” The potential tie-ups are part of a broader push by Chile and Argentina to deepen mining cooperation as some of the world’s biggest miners prepare to invest a combined $40 billion-plus in Argentina’s largely untapped copper belt. Major projects in San Juan Province include BHP Group and Lundin Mining Corp.’s Vicuña, Glencore Plc’s El Pachón and McEwen Copper Inc.’s Los Azules. (Bloomberg)
3
7
48
10,866
Next gen LLT - Obicetrapib can’t come soon enough while We pivot from our hyper focus on LDLc & short term ASCVD risk to long term protection against CKM (Cardio-Kidney-Metabolic) disease & neuro protection. $NAMS
4
301